Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas

Emre Kocakavuk; Kevin C. Johnson; Thais S. Sabedot; Hans Christian Reinhardt; Houtan Noushmehr; Roel G. W. Verhaak

doi:10.1093/neuonc/noad095

Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas

Emre Kocakavuk^*
, Kevin C. Johnson
, Thais S. Sabedot
, Hans Christian Reinhardt
, Houtan Noushmehr
, Roel G. W. Verhaak^*

^*Corresponding author for this work

Yale University
University of Duisburg-Essen
Henry Ford Health System
Amsterdam UMC - University of Amsterdam
Yale University School of Medicine
Amsterdam University Medical Centers

Research output: Contribution to journal › Comment/Letter to the editor › Academic

34 Downloads (Pure)

Original language	English
Pages (from-to)	1721-1723
Number of pages	3
Journal	Neuro-oncology
Volume	25
Issue number	9
DOIs	https://doi.org/10.1093/neuonc/noad095
Publication status	Published - 1 Sept 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

CDKN2A
IDH-mutant
astrocytoma
glioma
hemizygous deletion

Access to Document

10.1093/neuonc/noad095

Hemizygous-cdkn2a-deletion-confers-worse-survival-outcomes-in-idhmut-noncodel-gliomas.pdfFinal published version, 818 KBLicence: CC BY

Cite this

@article{8047f229bcea4ffd923713aa1f90c88a,

title = "Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas",

keywords = "CDKN2A, IDH-mutant, astrocytoma, glioma, hemizygous deletion",

author = "Emre Kocakavuk and Johnson, \{Kevin C.\} and Sabedot, \{Thais S.\} and Reinhardt, \{Hans Christian\} and Houtan Noushmehr and Verhaak, \{Roel G. W.\}",

note = "Funding Information: This work is supported by National Institutes of Health grants, R01CA237208, R21NS114873, R21CA256575, U2CCA252979, and P30CA034196 (RGWV). E.K. is supported by the Clinician Scientist Fellowship (FU 356/12-1) funded by DFG (Deutsche Forschungsgemeinschaft) and UMEA (University Medicine Clinician Scientist Academy) and a recipient of the Forbeck Scholar Award by the William Guy Forbeck Research Foundation.",

year = "2023",

month = sep,

day = "1",

doi = "10.1093/neuonc/noad095",

language = "English",

volume = "25",

pages = "1721--1723",

journal = "Neuro-oncology",

issn = "1522-8517",

publisher = "Oxford University Press",

number = "9",

}

TY - JOUR

T1 - Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas

AU - Kocakavuk, Emre

AU - Johnson, Kevin C.

AU - Sabedot, Thais S.

AU - Reinhardt, Hans Christian

AU - Noushmehr, Houtan

AU - Verhaak, Roel G. W.

N1 - Funding Information: This work is supported by National Institutes of Health grants, R01CA237208, R21NS114873, R21CA256575, U2CCA252979, and P30CA034196 (RGWV). E.K. is supported by the Clinician Scientist Fellowship (FU 356/12-1) funded by DFG (Deutsche Forschungsgemeinschaft) and UMEA (University Medicine Clinician Scientist Academy) and a recipient of the Forbeck Scholar Award by the William Guy Forbeck Research Foundation.

PY - 2023/9/1

Y1 - 2023/9/1

KW - CDKN2A

KW - IDH-mutant

KW - astrocytoma

KW - glioma

KW - hemizygous deletion

UR - https://www.scopus.com/pages/publications/85169847994

UR - https://www.ncbi.nlm.nih.gov/pubmed/37329568

UR - https://www.scopus.com/pages/publications/85169847994

U2 - 10.1093/neuonc/noad095

DO - 10.1093/neuonc/noad095

M3 - Comment/Letter to the editor

C2 - 37329568

SN - 1522-8517

VL - 25

SP - 1721

EP - 1723

JO - Neuro-oncology

JF - Neuro-oncology

IS - 9

ER -

Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas

UN SDGs

Keywords

Access to Document

Other files and links

Cite this